查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1967751

过敏诊断和治疗市场－全球产业规模、份额、趋势、机会和预测：按类型、按过敏原类型、按检测类型、按地区和竞争对手划分，2021-2031年

Allergy Diagnostics and Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Allergen Type, By Test Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球过敏诊断和治疗市场预计将从 2025 年的 363.3 亿美元成长到 2031 年的 576.2 亿美元，复合年增长率为 7.99%。

此领域涵盖用于识别和管理特定过敏原引起的超敏反应的医疗设备、检测套组和药物干预措施。市场成长的主要驱动因素是全球过敏性疾病（例如过敏性鼻炎和食物过敏）盛行率的不断上升，这些疾病需要独特的临床管理策略。此外，都市化加快和污染加剧导致人们更多地暴露于环境因素，这成为需要医疗保健的患者群体不断扩大的主要驱动力。

市场概览
预测期 2027-2031
市场规模：2025年 363.3亿美元
市场规模：2031年 576.2亿美元
复合年增长率：2026-2031年 7.99%
成长最快的细分市场 诊断
最大的市场 北美洲

儘管有这些积极迹象，但某些免疫疗法方案和先进诊断试剂盒的高成本构成了市场准入的重大障碍，限制了对成本敏感的开发中国家患者的就医机会。不完善的报销机制往往会加剧这种经济障碍，减缓创新治疗方法的推广。气喘与过敏基金会在2024年发布的报告凸显了这项公共卫生挑战的严峻性，报告显示，美国有超过1亿人患有过敏性疾病。

市场驱动因素

免疫疗法和生物製药的日益普及是市场成长的主要驱动力，反映出治疗策略正从缓解症状转向缓解疾病。临床医生经常开立口服和经皮免疫疗法等先进疗法，这些疗法已被证明能有效帮助患者对有害过敏原脱敏。例如，美国过敏、气喘和免疫学会 (ACAAI) 在 2025 年 11 月的年会上宣布，使用 Viaskin 花生贴片治疗的婴儿中，超过 70% 的人在三年后对特定花生蛋白水平产生了耐受性。这种临床疗效正在推动商业性成功，ALK-Abello 公司于 2025 年 11 月发布的「2025 年第三季展望更新」印证了这一点。该报告将全年销售成长预期（以该地货币计算）上调至 13-15%，因为使用免疫疗法产品的患者数量不断增加。

同时，诊断调查方法的技术进步提高了过敏原检测的速度和准确性，加速了产业成长。诸如成分降解诊断 (CRD) 和分子诊断等创新技术能够精确识别特定的过敏原蛋白，最大限度地减少传统皮肤点刺试验中常见的交叉反应问题。这种发展趋势推动了对个人化管理和精准医疗的需求，使医疗保健提供者能够识别更详细的过敏原资讯。例如，赛默飞世尔科技公司 2025 年 4 月发布的 2024 财年年度报告显示，其专业诊断业务创造了 45.1 亿美元的收入，这体现了该领域重要的经济意义，也印证了其在全球范围内对先进诊断工具的强劲投资。

市场挑战

特定免疫疗法方案和先进诊断试剂盒的高成本是全球过敏诊断和治疗市场的主要限制因素。儘管精准医疗在临床上至关重要，但长期减敏疗法和分子诊断检测的高昂费用阻碍了市场渗透，尤其是在价格敏感型经济体中。因此，医疗服务提供者和患者往往依赖抗组织胺药物等传统对症治疗，而非寻求根治性疗法。这种经济阻力减少了潜在治疗患者的数量，阻碍了对新疗法的需求成长，并妨碍了市场充分利用全球日益增长的过敏患者群体。

由于报销体係不足以抵销现代过敏症治疗的成本，经济障碍进一步加剧。当保险公司限製或拒绝承保特定诊断和生物製药时，由此产生的自付费用对许多患者来说难以承受。根据欧洲过敏与临床免疫学会估计，到2024年，过敏性疾病的直接医疗费用预计在每位患者每年1823欧元至6656欧元之间。如此高昂的人均费用表明，经济可及性仍然是一个重大瓶颈，直接限制了产生收入，并阻碍了先进治疗方案的广泛应用。

市场趋势

穿戴式生物感测器的出现，使得消费者能够在临床环境之外识别饮食和环境因素，从而改变预防性医疗保健方式，实现即时过敏原检测。这些携带式设备超越了对产品标籤的依赖，利用电化学感测和先进的分子印迹聚合物技术来检测空气和食物中的微量过敏原，让商业性即时安心。 FoodBev Media 2024 年 8 月发布的报告《Amulet 完成 A 轮融资 580 万美元，推出携带式食物过敏原感测器》强调了这项创新技术的商业潜力。报告指出，Amulet 已筹集 580 万美元，用于扩展其技术，以便随时随地检测麸质和花生等常见过敏原。

此外，基于微生物组的治疗方法的进步标誌着治疗策略正从传统的脱敏和对症治疗转向治疗导致过敏性超敏反应的根本原因——肠道菌群异常（菌群失调）。这一趋势强调了具有恢復肠道微生物多样性、调节免疫反应和预防婴幼儿「过敏进程」潜力的生物製药产品（LBPs）。例如，BioSpace在2024年3月发表的一篇报导《Siolta Therapeutics完成C轮资金筹措，筹集1200万美元用于临床开发》中报道，该公司已获得1200万美元资金，用于推进其旗舰候选药物STMC-103H的研发。 STMC-103H是一种预先设定的联合疗法，旨在预防新生儿食物过敏和异位性皮肤炎等过敏性疾病的发生。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球过敏诊断与治疗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 按类型（诊断、治疗）
    • 过敏原类型（食物、吸入物、药物、其他过敏原）
    • 依测试类型（生物测试、试管内测试）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美过敏诊断与治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲过敏诊断与治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区过敏诊断与治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲过敏诊断和治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲过敏诊断与治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球过敏诊断与治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Thermo Fisher Scientific, Inc.
  • R-Biopharm AG
  • DASIT Group SPA
  • AGILUS DIAGNOSTICS LTD.
  • AESKU.GROUP GmbH
  • bioMerieux SA
  • Siemens Healthineers AG
  • STALLERGENES GREER International AG
  • HYCOR Biomedical, LLC
  • Minaris Medical America, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23905

The Global Allergy Diagnostics and Therapeutics Market is projected to expand from USD 36.33 Billion in 2025 to USD 57.62 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 7.99%. This sector encompasses medical devices, assay kits, and pharmaceutical interventions designed to identify and manage hypersensitivity reactions to specific allergens. Market growth is primarily fueled by the increasing global prevalence of allergic conditions, such as allergic rhinitis and food allergies, which require distinct clinical management strategies. Additionally, rising urbanization and escalating pollution levels act as key drivers by intensifying exposure to environmental triggers, thereby widening the patient demographic in need of medical attention.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 36.33 Billion
Market Size 2031USD 57.62 Billion
CAGR 2026-20317.99%
Fastest Growing SegmentDiagnostics
Largest MarketNorth America

Despite these positive indicators, the market encounters significant obstacles due to the high costs associated with specific immunotherapy regimens and advanced diagnostic panels, which limit patient access in cost-sensitive developing nations. This financial hurdle is frequently exacerbated by insufficient reimbursement frameworks that slow the broad adoption of innovative treatments. Highlighting the magnitude of this public health challenge, the Asthma and Allergy Foundation of America reported in 2024 that allergic conditions impacted over 100 million individuals in the United States.

Market Driver

The increasing adoption of immunotherapy and biologics serves as a major catalyst for market growth, marking a shift from symptomatic relief to disease-modifying strategies. Clinicians are frequently prescribing advanced treatments, such as oral and epicutaneous immunotherapy, which have proven highly effective in desensitizing patients to dangerous allergens. For example, the American College of Allergy, Asthma & Immunology revealed at its Annual Meeting in November 2025 that over 70% of toddlers treated with the Viaskin Peanut Patch achieved tolerance to specific peanut protein levels after three years. This clinical efficacy is driving commercial success, as evidenced by ALK-Abello's November 2025 'Q3 2025 Outlook Update', which raised full-year revenue growth projections to 13-15% in local currencies due to higher patient volumes for immunotherapy products.

Concurrently, technological advancements in diagnostic methodologies are accelerating sector growth by improving the speed and accuracy of allergen detection. Innovations such as component-resolved diagnostics (CRD) and molecular diagnostics enable the precise identification of specific allergic proteins, thereby minimizing cross-reactivity issues common with traditional skin-prick tests. This evolution facilitates the demand for personalized management and precision medicine, allowing providers to identify sensitivities with granular detail. Demonstrating the economic significance of this segment, Thermo Fisher Scientific's '2024 Annual Report' from April 2025 noted that its Specialty Diagnostics business achieved $4.51 billion in revenue, underscoring the strong global investment in advanced diagnostic tools.

Market Challenge

The high costs associated with specific immunotherapy regimens and advanced diagnostic panels present a major restraint on the Global Allergy Diagnostics and Therapeutics Market. Although precision medicine is clinically necessary, the substantial financial requirements for long-term desensitization therapies and molecular diagnostic assays hinder market penetration, especially in price-sensitive economies. Consequently, healthcare providers and patients often resort to conventional symptomatic treatments, such as antihistamines, rather than pursuing curative interventions. This economic friction reduces the addressable patient population and retards the volume growth of novel therapeutics, thereby preventing the market from fully leveraging the rising global prevalence of allergies.

This financial obstacle is further compounded by inadequate reimbursement structures that frequently fail to offset the expenses of modern allergy management. When insurance providers restrict or deny coverage for component-resolved diagnostics or biologics, the resulting out-of-pocket costs become unmanageable for many patients. According to the European Academy of Allergy and Clinical Immunology, direct healthcare costs for allergic diseases in 2024 were estimated between €1,823 and €6,656 per patient annually. Such high per-capita expenses demonstrate why financial accessibility remains a critical bottleneck that directly limits revenue generation and obstructs the widespread adoption of advanced care solutions.

Market Trends

The emergence of wearable biosensors for real-time allergen detection is transforming preventative management by enabling consumers to identify dietary and environmental triggers outside clinical environments. Moving beyond reliance on product labeling, these portable devices employ electrochemical sensing or advanced molecular imprinted polymers to detect trace allergens in air and food, providing immediate assurance. The commercial potential of this innovation is highlighted by FoodBev Media's August 2024 report, 'Amulet secures $5.8m in Series A round to launch portable food allergen sensors', which notes that Amulet raised $5.8 million to scale technology allowing individuals to test for common allergens like gluten and peanuts on the go.

Additionally, the progression of microbiome-based therapeutic approaches signifies a shift toward treating the underlying dysbiosis responsible for allergic hypersensitivity, differing from traditional desensitization or symptomatic relief. This trend emphasizes live biotherapeutic products (LBPs) aimed at restoring gut microbial diversity to modulate immune responses and potentially halt the "atopic march" in early life. Illustrating significant investment in this area, BioSpace reported in March 2024, in the article 'Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development', that the company secured $12 million to advance its lead candidate, STMC-103H, a defined-consortia biotherapeutic developed to prevent the onset of allergic diseases like food allergies and atopic dermatitis in newborns.

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • R-Biopharm AG
  • DASIT Group SPA
  • AGILUS DIAGNOSTICS LTD.
  • AESKU.GROUP GmbH
  • bioMerieux SA
  • Siemens Healthineers AG
  • STALLERGENES GREER International AG
  • HYCOR Biomedical, LLC
  • Minaris Medical America, Inc.

Report Scope

In this report, the Global Allergy Diagnostics and Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Allergy Diagnostics and Therapeutics Market, By Type

  • Diagnostics
  • Therapeutics

Allergy Diagnostics and Therapeutics Market, By Allergen Type

  • Food
  • Inhaled
  • Drug
  • Other Allergens

Allergy Diagnostics and Therapeutics Market, By Test Type

  • vivo Test
  • vitro Test

Allergy Diagnostics and Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Allergy Diagnostics and Therapeutics Market.

Available Customizations:

Global Allergy Diagnostics and Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Allergy Diagnostics and Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Diagnostics, Therapeutics)
    • 5.2.2. By Allergen Type (Food, Inhaled, Drug, Other Allergens)
    • 5.2.3. By Test Type (vivo Test, vitro Test)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Allergy Diagnostics and Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Allergen Type
    • 6.2.3. By Test Type
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Allergy Diagnostics and Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Allergen Type
        • 6.3.1.2.3. By Test Type
    • 6.3.2. Canada Allergy Diagnostics and Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Allergen Type
        • 6.3.2.2.3. By Test Type
    • 6.3.3. Mexico Allergy Diagnostics and Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Allergen Type
        • 6.3.3.2.3. By Test Type

7. Europe Allergy Diagnostics and Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Allergen Type
    • 7.2.3. By Test Type
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Allergy Diagnostics and Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Allergen Type
        • 7.3.1.2.3. By Test Type
    • 7.3.2. France Allergy Diagnostics and Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Allergen Type
        • 7.3.2.2.3. By Test Type
    • 7.3.3. United Kingdom Allergy Diagnostics and Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Allergen Type
        • 7.3.3.2.3. By Test Type
    • 7.3.4. Italy Allergy Diagnostics and Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Allergen Type
        • 7.3.4.2.3. By Test Type
    • 7.3.5. Spain Allergy Diagnostics and Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Allergen Type
        • 7.3.5.2.3. By Test Type

8. Asia Pacific Allergy Diagnostics and Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Allergen Type
    • 8.2.3. By Test Type
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Allergy Diagnostics and Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Allergen Type
        • 8.3.1.2.3. By Test Type
    • 8.3.2. India Allergy Diagnostics and Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Allergen Type
        • 8.3.2.2.3. By Test Type
    • 8.3.3. Japan Allergy Diagnostics and Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Allergen Type
        • 8.3.3.2.3. By Test Type
    • 8.3.4. South Korea Allergy Diagnostics and Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Allergen Type
        • 8.3.4.2.3. By Test Type
    • 8.3.5. Australia Allergy Diagnostics and Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Allergen Type
        • 8.3.5.2.3. By Test Type

9. Middle East & Africa Allergy Diagnostics and Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Allergen Type
    • 9.2.3. By Test Type
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Allergy Diagnostics and Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Allergen Type
        • 9.3.1.2.3. By Test Type
    • 9.3.2. UAE Allergy Diagnostics and Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Allergen Type
        • 9.3.2.2.3. By Test Type
    • 9.3.3. South Africa Allergy Diagnostics and Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Allergen Type
        • 9.3.3.2.3. By Test Type

10. South America Allergy Diagnostics and Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Allergen Type
    • 10.2.3. By Test Type
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Allergy Diagnostics and Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Allergen Type
        • 10.3.1.2.3. By Test Type
    • 10.3.2. Colombia Allergy Diagnostics and Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Allergen Type
        • 10.3.2.2.3. By Test Type
    • 10.3.3. Argentina Allergy Diagnostics and Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Allergen Type
        • 10.3.3.2.3. By Test Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Allergy Diagnostics and Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. R-Biopharm AG
  • 15.3. DASIT Group SPA
  • 15.4. AGILUS DIAGNOSTICS LTD.
  • 15.5. AESKU.GROUP GmbH
  • 15.6. bioMerieux SA
  • 15.7. Siemens Healthineers AG
  • 15.8. STALLERGENES GREER International AG
  • 15.9. HYCOR Biomedical, LLC
  • 15.10. Minaris Medical America, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer